TrialPLoS medicine2021

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.

Graham H Jackson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.